Latest News

Brodalumab Performs in Phase 4 Studies of Moderate to Severe Psoriasis
Brodalumab Performs in Phase 4 Studies of Moderate to Severe Psoriasis

June 6th 2024

The results indicated improvement in PASI and sPGA scores as well as improvement in quality of life indicators in adults with moderate to severe psoriasis.

Generalized Pustular Psoriasis: Recent Advancements, Resources, and Cytokine Considerations
Generalized Pustular Psoriasis: Recent Advancements, Resources, and Cytokine Considerations

June 2nd 2024

Exploring Oral Options for Psoriasis Therapies
Exploring Oral Options for Psoriasis Therapies

June 1st 2024

Phase 2 Trial of ZL-1102 for Psoriasis Begins
Phase 2 Trial of ZL-1102 for Psoriasis Begins

May 29th 2024

Low Stress Resilience in Men Linked to Higher Risk of Psoriasis and Psoriatic Arthritis
Low Stress Resilience in Men Linked to Higher Risk of Psoriasis and Psoriatic Arthritis

May 29th 2024

Video Interviews
Podcasts
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
The Cutaneous Connection
The Cutaneous Connection: Episode 29- Do Diet and Supplements Affect Psoriasis?
The Cutaneous Connection
Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.